Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tadalafil and MUC1 Vaccine in HNSCC
NCT02544880Phase 1Completed
- Start
- Apr 2016
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of tadalafil in head and neck squamous cell carcinoma (HNSCC) (5 arms). Primary endpoints: Number of participants experiencing adverse events and/or treatment limiting-toxicities at 2 years and Rate of tumor-specific immune response to protocol therapy at 3.5 years. Started Apr 2016; status: completed.
02
Drugs
tadalafil
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT02544880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02544880.